clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03258762 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | Australia | Q408 |
P582 | end time | 2017-11-19 | |
P921 | main subject | toxoplasmosis | Q154878 |
P4135 | maximum age | 64 | |
P1050 | medical condition | toxoplasmosis | Q154878 |
P2899 | minimum age | 20 | |
P1132 | number of participants | 14 | |
P4844 | research intervention | calcium oxalate | Q412399 |
leucovorin calcium | Q27077063 | ||
P6153 | research site | GSK | Q212322 |
P859 | sponsor | GSK | Q212322 |
P580 | start time | 2017-09-25 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects |
Search more.